The place of long-acting injectable antipsychotics in the treatment of schizophrenia
- PMID: 36895432
- PMCID: PMC9989392
- DOI: 10.1177/20451253231157219
The place of long-acting injectable antipsychotics in the treatment of schizophrenia
Conflict of interest statement
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.M.K. reported having received honoraria for lectures and/or consulting from Alkermes, Allergan, Dainippon Sumitomo, Intracellular Therapies, Janssen, LB Pharma, Lundbeck, Karuna, Merck, Minerva, Neurocrine, Newron, Otsuka, Roche, Sunovion, and Teva. He is a shareholder of LB Pharma and The Vanguard Research Group. J.M.R. has received consulting honoraria from Teva, Janssen, and Karuna, and research grant funds from Alkermes.
References
-
- Keepers GA, Fochtmann LJ, Anzia JM, et al.. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2020; 177: 868–872. - PubMed
-
- Hasan A, Falkai P, Wobrock T, et al.. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318–378. - PubMed
-
- Wunderink L, Sytema S. Early medication discontinuation on long-term recovery outcome in first-episode psychosis: reply. JAMA Psychiatry 2014; 71: 208–209. - PubMed
-
- Ascher-Svanum H, Nyhuis AW, Stauffer V, et al.. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr Med Res Opin 2010; 26: 2403–2410. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources